ClinicalTrials.gg
RecruitingNCT06169241Updated Apr 13, 2026

Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

An Early Phase 1 interventional study of Beetroot extract and Placebo in Arterial Hypertension, Resistant Hypertension and Microvascular Function, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
123rd of 189
50 · median 80
Started
2023
with 5 others
Phase 1
2 of 209
1 open now
Primary completion
2026-12
later than 10 of 32 live
Registered
173rd of 209
by date
Lead sponsor
5 of 209
National Institute of Cardiology, Laranjeiras, Brazil

Among the 209 studies in Hypertension with a site in Brazil, this one is the 123rd largest by planned enrollment of the 189 interventional ones that give a count, is one of 6 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 10 of the 32 other live ones, and was the 173rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

03

Conditions studied

  • Arterial Hypertension
  • Resistant Hypertension
  • Microvascular Function
  • Nitrate Supplementation

Browse trials for

Keywords

  • microcirculation
  • capillary density
  • microvascular reactivity
  • systemic resistant hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.

Exclusion criteria

Exclusion Criteria:

  • neoplasms
  • heart failure
  • use of medications with nitrate in their formula
  • patients undergoing renal denervation
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    The placebo group will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

    Dietary Supplement: Placebo

  • Active comparator
    Beetroot extract

    Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.

    Dietary Supplement: Beetroot extract

Interventions

  • Dietary supplementBeetroot extract

    Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.

  • Dietary supplementPlacebo

    The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

06

What researchers measure

Primary outcomes

  1. Assessment of blood pressure evolution

    Evaluation using Ambulatory Blood Pressure Monitoring: systolic, diastolic and mean arterial pressures

    Time frame: 60 days

07

Study locations

1 of 1 sites recruiting
  • National Institute of Cardiology
    Rio de Janeiro, 21040-360, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 44 non-industry phase 1 interventional studies under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 37 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169241
Lead sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Eduardo Tibirica, MD, PhD (Senior Researcher, National Institute of Cardiology, Laranjeiras, Brazil) — Principal investigator
First posted
Dec 13, 2023
Start date
Nov 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

EDUARDO TIBIRICA, MD, PhD
Contact
etibi@uol.com.br
+55-21-99914-6075

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion